Objective: To investigate the correlation between serum fibroblast growth factor 21 (FGF21), proliferator-activated receptor γ (PPARγ) and coronary artery stenosis (CAS). Methods: A total of 60 patients with coronary heart disease (CHD) were selected as CHD group and 30 healthy subjects were selected as control group. Serum FGF21 and PPARγ levels were measured in both groups. All subjects were quantified by Gensini scoring method for CAS degree, and then the relationship between FGF21, PPARγ and CAS was discussed. Results: Coronary angiography showed that there were 26 cases of single vessel disease, 19 cases of double vessel disease and 15 cases of triple vessel disease in CHD group. The levels of FGF21 and PPARγ in CHD group were significantly higher than those in control group (P＜0.05). The levels of FGF21 and PPARγ in patients with three-branch disease were higher than those in patients with two-branch disease (P＜0.05), and significantly higher than those in patients with single-branch disease (P＜0.01). The levels of FGF21 and PPARγ in patients with double-branch disease were higher than those in patients with single-branch disease (P＜0.05). After grouping by Gensini score, the levels of FGF21 and PPARγ in groups 0 to 1 were the lowest, the levels of FGF21 and PPARγ in groups greater than 40 were the highest, and the levels of FGF21 and PPARγ in groups 21 to 40 and > 40 were higher than those in groups 2 to 20 (P＜0.05). Partial correlation analysis showed that serum FGF21 was positively correlated with the number of CAS lesions (r=0.472, P＜0.05), and with Gensini score (r=0.516, P＜0.05). PPARγ was positively correlated with the number of CAS lesions (r=0.368, P＜0.05) and with Gensini score (r=0.335, P＜0.05). Spearman correlation analysis showed that there was a positive correlation between FGF21 and PPARγ (r=0.412, P＜0.05). ROC curve analysis indicated that serum FGF21 concentration was positively correlated with CHD (P＜0.05). Conclusion: Serum FGF21 and PPARγ levels in CHD patients were higher than those in healthy people, and were positively correlated with the degree of coronary artery stenosis, which may predict and evaluate the severity of coronary artery disease.
WANG Yakun
,
WANG Wenjing
,
SONG Jingjie
. The study of serum FGF21、 PPARγ and coronary artery stenosis correlation[J]. Journal of Baotou Medical College, 2023
, 39(10)
: 38
-41
.
DOI: 10.16833/j.cnki.jbmc.2023.10.008
[1] Seo JA, Kim NH. Fibroblast growth factor 21:a novel metabolic regulator[J]. Diabetes Metab J, 2012,36(1):26-28.
[2] Tian JW, Hu SY, Wang F, et al. PPARG, AGTR1, CXCL16 and LGALS2 polymorphisms are correlated with the risk for coronary heart disease[J]. Int J Clin Exp Pathol, 2015,8(3):3138-3143.
[3] 丁蓉,郝晶,张振兴,等. 血清成纤维细胞生长因子23和Klotho对川崎病合并冠状动脉损伤的诊断价值[J]. 中国医药,2021,16(2):196-199.
[4] 高宏伟,王远,代佩,等. 冠心病患者中血清成纤维细胞生长因子21与胆固醇酯转运蛋白和冠状动脉粥样硬化严重程度之间的相关性研究[J]. 中国心血管病研究,2020,18(11):984-989.
[5] Lee CH, Woo YC, Chow WS, et al. Role of circulating fibroblast growth factor 21 measurement in primary prevention of coronary heart disease among Chinese patients with type 2 diabetes mellitus[J]. J Am Heart Assoc, 2017,6(6):e005344.
[6] Shen Y, Zhang XL, Xu YT, et al. Serum FGF21 is associated with future cardiovascular events in patients with coronary artery disease[J]. Cardiology, 2018,139(4):212-218.
[7] 陈海峰,吴峰,卢楠,等. 血清成纤维细胞生长因子21、脂联素与冠状动脉性心脏病的相关性[J]. 中华高血压杂志,2016,24(8):758-762.
[8] Cao FY, Wang SP, Cao XR, et al. Fibroblast growth factor 21 attenuates calcification of vascular smooth muscle cells in vitro[J]. J Pharm Pharmacol, 2017,69(12):1802-1816.
[9] 杨文聪,尹建蓝,黄芳,等. 冠心病患者血清FGF21、PPARγ水平与冠状动脉狭窄程度的相关性[J]. 广东医学,2019,40(12):1817-1819.
[10] 耿田欣,李波,许尧,等. CD137信号调控巨噬细胞M1/M2极性转变促进血管新生[J]. 中华心血管病杂志,2020,48(6):500-506.
[11] 宋小丽. 血清组织型纤溶酶原激活物-抑制剂复合物和膜联蛋白A2及核转录过氧化物酶增殖体激活受体γ与冠心病患者冠状动脉狭窄程度相关性及其对预后的影响[J]. 中华实用诊断与治疗杂志,2021,35(6):556-560.
[12] 魏鹏歌,黄健. PPARγ-LXRα-ABCA1 信号通路在动脉粥样硬化防治研究新进展[J]. 国际遗传学杂志,2019,41(2):176-180.
